We currently have agreements with four suppliers for COVID-19 vaccines. These are Pfizer, Janssen Pharmaceutica, Novavax and AstraZeneca.
Last updated: 8 March 2021
On this page:
New Zealand is securing COVID-19 vaccines through Advance Purchase Agreements with pharmaceutical suppliers. We have agreements with four suppliers.
The Government has signed an advance purchase agreement for 8.5 million additional doses from Pfizer. Enough to vaccinate 4.25 million people. These vaccines are expected to arrive in New Zealand during the second half of the year.
Our first COVID-19 vaccine agreement was for 1.5 million COVID-19 vaccines from Pfizer.
The decision to make Pfizer our primary vaccine provider includes:
- it's shown to be approximately 95% effective against symptomatic COVID-19, seven days after receiving two doses
- all people in New Zealand will have the chance to access the same vaccine
- dealing with one vaccine will simplify our vaccine roll-out.
An in-principle agreement has been signed with Janssen Pharmaceutica to purchase up to 5 million COVID-19 vaccines. The Janssen vaccine is likely to be a single dose.
We’ve agreed with Novavax to purchase 10.72 million doses of a COVID-19 vaccine. This vaccine needs two doses. Enough for 5.36 million people.
We’re not likely to receive this vaccine until later in 2021.
An Advance Purchase Agreement of 7.6 million doses was signed with AstraZeneca. This vaccine needs two doses which is enough for 3.8 million people.
AstraZeneca vaccine is fridge-stable, which may allow for a more efficient rollout. This means it’s compatible with our existing storage and distribution channels.
Monitoring international use of AstraZeneca
There are reports that AstraZeneca may be ineffective for people aged over 65. We consider it to be a credible contribution to our portfolio, reinforced by the fact it’s also purchased by Australia, Canada, the United Kingdom, the European Union and the United States.
The widespread use of AstraZeneca overseas will help us understand the benefits in the wider population. This includes the level of protection and whether the vaccine reduces transmission of the virus.